[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-skin-graft-versus-host-disease-gvhd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-skin-graft-versus-host-disease-gvhd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100654620","phase-1-topical-ruxolitinib-in-acute-skin-gvhd-graft-versus-host-disease-100654620",false,"NCT07801248","Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)","Efficacy of Topical Ruxolitinib in Acute Skin GVHD: A Pilot Study","Inclusion Criteria:\n\n* Age ≥2 through age 35 years\n* Acute skin GVHD (any grade).\n* Underlying diagnosis of malignancy.\n* No concurrent systemic immune suppression to treat acute GVHD. This excludes agents like calcineurin inhibitors, mycophenolate mofetil, and abatacept which prevent acute GVHD and are not used for treatment as per clinical practice may continue.\n* Use of prior topical steroids or topical tacrolimus will be allowed but these will need to be discontinued 24 hours prior to study enrollment.\n\nExclusion Criteria:\n\n* Active uncontrolled skin infections.\n* History of allergic reactions to topical ruxolitinib.\n* Concomitant steroids or have received investigational therapies within the previous 30 days.","ALL","2 Years","35 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to see if ruxolitinib, a Janus Kinase (JAK) 1\u002F2 inhibitor, is safe for people who have acute skin graft versus host disease (GVHD) following allogenic hematopoietic stem cell transplantation (HSCT).",[27],"Acute Skin Graft Versus Host Disease (GVHD)","NOT_YET_RECRUITING","2026-09-02",{"date":31,"type":32},"2026-09-08","ACTUAL",{"date":34,"type":21},"2026-10-01",{"date":36,"type":21},"2029-10",{"name":38,"class":39},"Children's Hospital Medical Center, Cincinnati","OTHER"]